876
www.dermatologiepropraxi.cz34080430107651332012142633073344084494765225425906406597037527798268779039459851004102010601099
19756558026012657111168
PŘEHLEDOVÉ4549207012660124182256312369444520587645
ČLÁNKY5216207012660115187259327395
Lokálna314436501062968104146177219258
liečba34183650106294779113149190
bazocelulárneho362336501063474108147182214246286317358394435467508549
karcinómu418836501063375111145163204245299339
–4543365010645
súčasný460436501063071105147181222259
stav48793650106306399134
a5029365010638
nové508236501064080118150
perspektívy524736501063364100135169200236270288326365
DERMATOLOGIE45948043010758102149221276314375417477536557600
PRO5216804301074591154
PRAXI5391804301074591148201221
6.3456200853652
Geisse418621083448095122149184
J,6236210832437
Caro680621083417495133
I,8346210831528
Lindholm883621083314785125163202218276
J,11806210832537
et12386210833456
al.1315621083324861
Imiquimod1397621083157389128166181240278318
5%17366210833586
cream1843621083315387120178
for345721083185678
the441721083226095
treatment554721083224377109131189224262284
of8567210833857
superficial9317210832764103138160180197229244276291
basal1241721083387198131146
cell140672108331658095
carcinoma:1520721083316485116131169207266298310
Results18497210833570971341493458210832250
from416821083184178137
two5748210832275113
phase7088210833978111138173
III,90282108315304659
randomized,981821083215593132171230245275309349362
vehicle-controlled13648210833266105120153168204227261298337359381419435450485525
studies.1910821083265088345921083395591119133
Journal5009210832464104126166199215
of7379210833858
the817921083226198
American93692108342102138161177210244284
Academy12419210834275109149185245277
of15409210833858
Dermatology.16209210834683105165199221260276316357390401
2004;50(5):722-733.34510210833468104141152188222241275293305338373407428459493526539
7.34511200853645
Roldán-Marín4111121083357490129161199222278311332348386
R,81811210833549
Toussaint-Caire88811210833266105131158191206244266286329362377398432
S.134111210833246
Imiquimod14071121083157388127165180238276316
5%174411210833485
as184911210833259
adjuvant1928112108332713451221083155285118156178
therapy5411221083226095116149188220
for7791221083195678
incompletely8751221083155385122180219235270292326342373
excised12671221083346697112138173212
infiltrative1498122108315537087102124146179201216249283
nodular179912210833876116153169201222
basal3451321083397298131147
cell506132108331648095
carcinoma6151321083316485116131169207266298
and92713210833270109
dermoscopy10501321083387294152191217249286326357
to142113210832259
monitor149313210835896135150172209231
treatment17371321083224377109131189224262284
response.3451421083215582120159198224259271
Dermatology63214210834580102160192214251267305345377
and102414210833270109
Therapy.114814210833372107128161200232242
2015;5(4):265-272.140514210833468100130141176194227244256291325358380411444479491
8.34515200853651
McKay41215210835486121153184
KM,61115210833591104
Sambrano73115210833265122160181214251288
BL,10351521083366780
Fox11311521083326999
PS,12451521083366880
et134115210833455
al.14121521083324759
Thickness14871521083327185116146184219245271
of177415210833755
superficial184515210832663101136157345162108317346580111126
basal4891621083397197129144
cell651162108332658094
carcinoma7631621083326484115129166204261293
(SBCC)10751621083184983124161181
predicts12741621083396093132146178201228
imiquimod15211621083147186124161175232270309
efficacy:18481621083345270871191513451721083316477
A433172108341
proposal4861721083385996135173199231246
for7431721083195677
a831172108332
thickness-based8751721083215973104133172206232258278318350376410449
definition13351721083397389106144158180194231269
of161617210833756
SBCC.168317210833367107144157
British1851172108336567193108133170
Journal3451821083246299120158189204
of56318210833756
Dermatology.63318210834579100158189210247262299338370379
2013;169(3):549-554.10261821083346798128138168198231250283299311345380412435468500534546
9.34519200853649
Roozeboom41319210833574112141175214253291350
MH,78219210835499112
Arits9131921083416278100128
AHHM,106019210834185130185198
Nelemans12771921083458096131189221259285
PJ,15811921083355567
et166719210833456
al.17421921083324760
Overall182119210834781115136169184199
treatment3452021083224377109131189224262284
success6432021083266396126160187214
after8712021083325176110131
treatment10162021083224478109131189224262284
of131520210833756
primary13862021083386076133166187221
superficial162120210832664103138160179196229244276291
basal1927202108338713452121083265975
cell435212108331658095
carcinoma:5452121083316485116132169208266298311
a871212108331
systematic9172121083265986109143201233255270302
review12342121083215587103138189
and143821210833270109
meta-analysis156221210835792114147170202240272288319346361387
of196421210833757
randomized3452221083205390128166223238267300339
and69622210833269107
nonrandomized81622210833774112133165202241278336350379412451
trials.1279222108322435889104130143
British1434222108335567193108133171
Journal16172221083246199120157189204
of183322210833756
Dermatology.19012221083458010134523210835790111148164202242274284
2012;167(4):733-756.64423210833569100130143173204237253286304315349383416438469502536549
10.3452420085366984
Sharquie44224210833270102122160197212246
KE,7012421083356981
Noaimi79524210834482115130187202
AA.10092421083418498
Basal11202421083356894126142
cell1274242108331658095
carcinoma:13812421083316485115130168206263295307
topical17012421083215897112144176191
therapy190524210832259943452521083205391122
versus4792521083316585112148174
surgical6652521083266283120135166198213
treatment.8902521083224376107128185220257278291
Journal11932521083246199119157189204
of140925210833755
the14772521083215893
Saudi158225210833264101139154
Society174825210833270102116150172205
of196525210833756
Dermatology34526210834581102160193214251267305345377
&73526210833972130169181
Dermatologic92926210834681102161193215252268306345361393
Surgery.13352621083326990129163185219229
2012;16(2):41-51.157726210833468100130142172203222256274286320351369403434444
11.3452720085356576
Kim43427210833450107
JYS,5532721083235990102
Kozlow6672721083357199114151201
JH,8802721083246780
Mittal9722721083536890113145160
B,114427210833547
et120327210833455
al.12702721083314659
Guidelines13412721083438094132166181196232267293
of164627210833655
care17132721083316383116
for18412721083185576
the19292721083215892
management34528210835790128160199234292327365387
of74728210833857
basal8202821083387198131146
cell982282108331658196
carcinoma.10942821083316485116131169207266298311
Journal142128210832462101122160193208
of164528210833756
the17172821083226095
American18282821083419913415517134529210833164102
Academy46229210834173106145180238268
of74629210833756
Dermatology.81729210834681102161193215252268306345377388
2018;78(3):540-559.122029210833468100131143176209228262279291326362397421455488520531
12.3453020085366782
van44030210833164101
Delft5533021083458095114138
LCJ,7043021083316995106
Nelemans8233021083447894128185217254280
PJ,11153021083355466
Kessels11933021083346894120155170196
JPHM,140130210832459102156169
et158330210833355
al.16513021083314658
Long-term172230210833168105144166188221241299
efficacy345312108334527088120153185219
of58031210833857
photodynamic65431210833877115137174213245284316374389421
therapy10923121083226095116149188219
with13283121083516689127
fractionated14723121083184073105129145183221253275309348
5-aminolevulinic183731210833456881461613453221083387692127159197213228265280312
acid6723221083326479118
20%80532210833468121
versus9413221083326687114152178
conventional113432210833168106138172210231247285323355371
two-stage152032210832174112135162185218257292
topical18273221083225998114146178194
methyl34533210835792115153183200
aminolevulinate55933210833289105142181197231264302317332370403424458
for10313321083195678
superficial112333210832664103138159179196228243275291
basal-cell14283321083397298131147169203236252267
carcinoma.17093321083326486117132170208266299312
Dermatology.34534210834581102160193214251267305345377387
2022;238(6):1044-1049.74734210833569101136149184218253272305323335365396432469492523555591624635
13.3453520085377186
Ceilley4533521083417692109125161194
RI,6693521083365366
Del75735210834784100
Rosso87935210833676104132172
JQ.10733521083247487
Current118235210834179101124159199222
modalities142535210835999141174191207230246283311
and175735210833373113
new189235210833975128
advances34536210833271104136174207240267
in62636210831452
the6923621083216094
treatment8003621083224377109131189224262284
of109736210833757
basal11673621083397298131147
cell1327362108332658196
carcinoma.14363621083326586117132170208266299312
International1761362108315537510913016820122223834537210833776108123
Journal48437210832462100121160192208
of70737210833757
Dermatology.77937210834581102160193214251267305345377387
2006;45(5):489-498.118137210833469105140153187220238271290302336372406430467500535548
14.3453820085356782
Habashy43938210834375113145170207236
S,68738210833244
Jafri743382108324557394109
A,86438210834054
Osman93038210834672128159196
HO,113838210834390100
et125038210833355
al.13173821083314658
Hedgehog138738210834377115153187224261299
pathway16983821083387091128177209239
inhibitors:1949382108314513453921083375291106129165187214226
Clinical5843921083395469107121153186201
implications79839210831471110126141173205227242279318344
and115439210833270108
resistance1275392108321548196121144177215247280
in156839210831452
the16323921083226095
treatment17393921083224377108130188222260281
of21416210833757
basal2213621083397298131147
cell237562108331658096
carcinoma.2486621083316485116131169207266298311
Cureus.2813621083407697131169195209
2021;13(3):13859.30376210833469101133141171201219253270282312342376410442453
15.2141720085366780
Nguyen22327210834482119149182219
NM,24627210834598111
Cho25847210833976113
J.27087210832435
Hedgehog27547210834478116154188225262300
pathway3065721083387091128177208238
inhibitors3314721083145188102140154176211232258
as35837210833157
targeted36517210832153731101442141821083225594
cancer22478210833163100132165185
therapy2445821083215993114146184215
and26728210833269108
strategies2792821083264869102123156194209243269
to30738210832258
overcome31438210833869102123153190247282
drug3437821083385896134
resistance.3583821083215481951201431752122141921083316374
International2226921083155171104124161192212227263300331345
Journal2582921083246197117155185200
of27939210833654
Molecular28589210835491106139171207221252272
Sciences.3141921083326377110147177210235248
2022;23(3):1733.3399921083346798132143177210227259275286314342375407418
16.21411020085366985
Gambini224110210834476134173189227242
D,249810210834556
Passoni25691021083356793120158196211
E,279510210833346
Nazzaro285610210834477106137171192229
G,310010210834457
et317210210833456
al.32431021083324760
Basal33181021083356894128143
cell3476102108331658095
carcinoma35861021083316485116131169208214111210835789
and224311210833169108
hedgehog236311210833872112150185223261300
pathway26751121083397293131181213244
inhibitors:29321121083145289104143158181217239266278
Focus322311210833269101139165
on340011210833775
immune348811210831572129166204239
response.374011210832054214112210832665104142169204216
Frontiers23721221083335289128149165199221248
in263512210831553
Medicine.270312210835590129144176191229264276
2022;9.299512210833468101136148183194
17.21411320085366876
Yin22331321083355189
VT,23371321083367382
Sniegowski24341321083337086120160198249276306322
M,277113210835568
Esmaeli285513210833260117150185200215
B.308613210833548
Indications31491321083155392107139172194209247286312
and347613210833270109
limitations36001321083153088103125158180195214114210833776102
of225914210833857
vismodegib23321421083324874132170210244284299338
for26871421083185677
basal27811421083387198131146
cell2944142108331658095
carcinoma.30561421083316485116131169207266298311
JAMA338414210832464120161
Ophthalmology.356214210834787125147185217233214115210835796112150189221231
2014;132(7):905-906.238815210833468100131143173203235253287307319354389424446481516552565
18.21411620085366985
Cozzani224616210834077105136170208223
R,248816210833650
Aguila255716210834179117132147179
R,275616210833549
Carrizo28251621083397293115131160197
M,304216210835467
et312916210833456
al.32041621083324861
Efficacy3284162108333506886118151183217
and352016210833270109
safety36481621083266078113135169
profile21411721083396097115132147182
of233917210833857
vismodegib24121721083324874131170209244284299338
in276617210831553
a2835172108332
real-world28831721083215587102124176214236251290
setting31901721083266183107123160199
cohort340617210833168106145166191
of361317210833857
patients3686172108339729410921411821083347294121
with22761821083516689127
advanced241718210833271104136175207240280
basal27111821083397298131147
cell2872182108331658095
carcinoma29811821083316485117132169208266298
in329318210831553
Argentina.336018210834162100135173195210248280294
International3668182108314527410812921411921083387092107145183216231
Journal238719210832463101122161193208
of261119210833756
Dermatology.268319210834580101160192214251267305345377387
2020;59(5):627-632.308519210833468101135148183215235268286298334367400419456490522535
19.21412020085366778
ClinicalTrials.gov.22292021083405366103116146177191223239253283297321333370406437445
Trial2684202108332486292106
of279920210833755
Patidegib2864202108335658599136169206220257
Gel31312021083437791
2%,32322021083348496
4%,33382021083348395
and344320210833167105
Vehicle355720210833667103117147160193
to376020210832257
Decrease214121210834578108127159189213246
the23962121083225790
Number249621210834379134171204223
of272921210833754
Surgically27922121083326786122135165196209222252
Eligible3053212108332455895108145159191
Basal32542121083346590120134
Cell3397212108340718598
Carcinomas35042121083397089118131167203258288313
in214122210831551
Gorlin220322210834381101115129165
SynDrome23792221083336198143163199256290
Patients26792221083356686100133170190216
–2906222108335
Full2952222108332678195
Text30572221083336292115
View.31832221083365184134143
[cited3337222108318476182114152
202335002221083346798132
Mar364222210835586105
1].37582221083344859
Available214123210834069100113126156193207240
from:23902321083183873129140
https://clinicaltrials.gov/ct2/show/NCT02762084.253923210833757791161411511761952212352482832973263573713914104244544674915035405766056276536757097337567918278768989419801013104510761107113711681200123312671278
20.21412420085367288
ClinicalTrials.gov.22492421083405571109124156189205239256272304320346360399437470480
Clinical27492421083405671109124156189205
Trial2975242108332506598113
of310924210833757
Patidegib31862421083366890105144179219234274
Gel34802421083448096
2%,359624210833587101
4%,371724210833586100
and214125210833271110
Vehicle227225210833670109124157172208
Applied250125210834181121137153188228
Once275025210834887120154
or292525210833860
Twice30062521083338096129163
Daily31902521083467994110142
to335325210832259
Decrease343325210834682115137172204231267
the37212521083226096
GLI121412621083447691123
Biomarker22782621083365189147180201231266287
in258026210831452
Sporadic264726210833271110132165204219251
Nodular291326210834483122160175207228
Basal31562621083366995128144
Cell33142621083407490105
Carcinomas34342621083397293124140177216274306333
–3782262108335
Full2141272108332698499
Text22572721083326394119
View.23922721083365287138149
[cited2557272108319496487120160
2023273327210833469101136
Mar288627210835487108
1].30102721083345062
Available308827210834172105120135167207222257
from:33622721083184077136148
https://clinicaltrials.gov/ct2/show/NCT02828111.35262721083385984123150162189210238254269214128210833853851171331551771922242402662793183563884114404645005275515896276787027487898248588919259589921024105210791089
21.21412920085377387
Villani2251292108337557289123163180
A,245529210834258
Potestio25372921083367599135164189206246
L,280729210833247
Fabbrocini287829210833465107149172212247263304320
G,322229210834560
et330629210833559
al.33892921083335065
New347729210834684138
emerging36382921083359613415721413021083395594135
treatment22983021083224580113136196233272295
options261530210833879103119159198226
for28633021083195881
advanced296630210833373107142181215250291
basal327930210833974101136153
cell34543021083326783100
carcinoma35763021083326688121137176216214131210835892
and225531210833271112
squamous238931210832667106139199238278305
cell27163121083326784100
carcinoma.28383121083326688120136176215275309323
Advances318331210834281115149189222257285
in349031210831554
Therapy.356731210833373109132166206239250
2022;39(3):1164-1178.214132210833469103138151187221241275293305336364396433457488517547581595
22.21413320085367288
Verkouteren22423321083366890120158196218252273307345
BJA,260033210833660100114
Sinx27273321083334885117
KAE,285733210833579112125
Reinders29953321083357086123162197219246
MGHC,325433210835499143184197
et346433210833457
al.35343321083314760
Update360733210834382122154176210
on214134210833774
hedgehog222834210833771109148182219257295
pathway25353421083397192129179211241
inhibitor27883421083155289103142157179215236
therapy30363421083215893113146184214
for32633421083185576
patients33513421083387091106140177198225
with35883421083506587124
basal37253421083387021413521083265975
cell2230352108332658196
naevus234135210833769104137175201
syndrome25573521083265998137158195253288
or286035210833759
high-frequency29333521083385392130152172194228268305340378410444
basal33923521083387198131146
cell3553352108331658196
carcinoma.36633521083326486117132214136210833876134166180
Acta23363621083417297129
Dermato-Venereologica.248136210834580102160192214251274310343381416437471510526564604619651684697
2022;102:980.319336210833468101136148178210243255290325361373
23.21413720085367287
Zeng224637210833871110149
L,241237210833145
Gowda247537210834382133172204
BH,26973721083358093
Ahmed280737210834179137172212
MG,303637210835599113
et316637210833456
al.32403721083324760
Advancements331837210834179112144182215248306341379401429
in376437210831553
nanoparticle-based214138210833870109148188221243267283315331366390430463490526566
treatment27273821083224478111133192227266287
approaches303538210833272112134171205237276311338
for33943821083185778
skin34933821083275773112
cancer362638210833164103135169191
therapy.21413921083226095116149188219229
Molecular238639210835493109143176214229261282
Cancer.268439210834073111143176198208
2023;22(1).290739210833469101136148183217235266281292
24.3937620085367186
Souto40376210833271109131168
EB,4219621083336981
Macedo43146210835587119153193231
AS,4559621083417588
Dias-Ferreira4661621083456193119140174208229251285300322355
J,50306210832436
et50806210833456
al.5150621083324760
Elastic5224621083334880107130145177
and54156210833270109
ultradeformable553862108337533937721083224376115150169207228287319358374409
liposomes4363721083153069108135173231266293
for4673721083185678
transdermal4768721083214376114140179214235294326341
delivery5126721083387389104136171192226
of53697210833756
active5442721083326489104136171
pharmaceutical39378210833978111132191224257291329352368400433449
ingredients4407821083155393114149189204239278300328
(apis).4756821083184989105131149160
International4937821083155375109131170203225240279318350366
Journal53248210832463102123162195211
of55568210833757
Molecular39379210835493109144176214229262283
Sciences.4235921083336580115153185219245259
2021;22(18):9743.45099210833469101133141176211228260291309321356389419452464
25.39371020085367287
Zielińska40411021083385388103118156182212246
A,430410210834155
Szalata43761021083336195110143164197
M,459010210835568
Gorczyński467610210834382104135165199238264294311
A,500410210834155
et507610210833457
al.51501021083324760
Cancer522710210834073111143177198
nanopharmaceuticals:544310210833769108146393711210833876108129186218249282320342357388420435461473
Physicochemical442211210833572102128143174210242280314371386417449464
characterization489911210833168100120153184208241262277305338360374412450
and536111210833169107
in548011210831552
vitro/in55451121083314639371221083224380105121159
vivo41111221083324880118
applications.424412210833271111127142174206228243281320346360
Cancers.461912210834073111143177198225239
2021;13(8):1896.487312210833468101133141171201219253271283313344378413427
26.39371320085367288
Calienni40461321083407489105140178217232
MN,4299132108355101114
Febres-Molina443413210833367107129164191212269308324340378411
C,486613210834053
Llovera49401321083324886119154175209
RE,51701321083357083
et527413210833457
al.53521321083324761
Nanoformulation54331321083467811715639371421083185678136174189221243258296335
for42911421083195678
potential438814210833978100134172193208240256
topical46631421083225999114146179194
delivery48771421083387389104136170192226
of512214210833757
Vismodegib51981421083365279136174214249289304343
in556014210831553
skin39371521083265672110
cancer406615210833164102134168189
treatment.42731521083224378109131189224262284297
International45891521083155374108129168200222237275313346361
Journal496915210832462100121160192208
of519515210833757
Pharmaceutics.5270152108335731051261842172492833203937162108322376997110
2019;565:108-122.406216210833569101131143179213247258287319354377408438472485
27.39371720085367180
Morton403617210835493114139176214
CA,42701721083408397
Dominicus438717210834584142157195210242280306
R,471317210833549
Radny478217210833668108146176
P,497817210833540
et503817210833456
al.51141721083314760
A5194172108341
randomized,52541721083215492131169228243272306345358
multinational,393718210835896112135150189222244259298337370385398
noninferiority,435618210833877116131170189224245261300322338361395405
phase478218210833978111138173
III49761821083153146
trial5043182108322446092108
to517218210832259
evaluate525218210833567101117155188210244
the55171821083226096
safety39371921083276180115138173
and413119210833271111
efficacy4263192108335547290123157190224
of450819210833858
BF-20045871921083367092124158195
aminolaevulinic480419210833291107145185201234270303342358373412428461
acid52861921083326581120
gel54281921083387490
vs.55391921083326074
methyl393720210835893115154185201
aminolaevulinate415820210833290106144182198231266298337352367406438460494
cream46722021083325388120178
in487020210831553
the49442021083216095
treatment50602021083214377109131190225263285
of536620210833756
nonaggressive54432021083387611514739372121083387798132159186201233267
basal42192121083397299132147
cell4381212108331658196
carcinoma44922121083316485116131169207265298
with48052121083506688127
photodynamic494721210833877115137174213245284316374389421
therapy.53832121083226095116149189220230
British3937222108335577295110136174
Journal412622210832463101122161193208
of435022210833756
Dermatology.442222210834580101160192214251267305345377387
2018;179(2):309-319.482422210833468100131143173203236255289307319354389424447480511541552
28.39372320085367288
Mohammadpour403923210835493131164221279312351390429467488
R,454123210833549
Dobrovolskaia460423210834584124145182214252268294324357372404
MA,502223210835597111
Cheney514723210834077112150185217
DL,53782321083457791
et548323210833456
al.55532321083324760
Subchronic393724210833270109142180201238276292324
and427624210833270109
chronic44002421083327091128166181213
toxicity46292421083215889104136151174207
evaluation48522421083346699114152184206221259298
of516524210833757
inorganic52372421083155391113151183221236268
nanoparticles552124210833769393725210833876115148169194209241257292318
for42742521083185678
Delivery43702521083458196111144178199233
Applications.462225210834180120136151183216237253291329355369
Advanced501025210834179112144182215248288
Drug531625210834667106145
Delivery5479252108346819711239372621083326687121
Reviews.407326210833671103119154205232245
2019;144:112-132.433426210833468100130143173204241253283310340361391421454466
29.39372720085367285
Tang40382721083336199138
W,419127210835867
Fan427427210833262100
W,438927210835867
Lau447227210833165102
J,459027210832436
et464227210833456
al.47142721083324760
Emerging478927210833391126147185200238277
blood–brain-barrier-crossing5082272108338549213117120724726930231735537741745047149350939372821083345575109131168195222237275314
nanotechnology427228210833770108147169203236274312350367405445477
for47702821083185678
brain48682821083396194109147
cancer503628210833164103135169190
theranostics.52472821083226095117150188226253277292324352366
Chemical393729210834078113171186218251266
Society421829210833371104119154176210
Reviews.444329210833570103118153204231245
2019;48(11):2967-3014.470329210833468100130143178214233264292307318354388423456475507541573604617
30.39373020085367186
McKay403530210835486120153184
KM,423130210833591104
Sambrano434730210833265122160182214251289
BL,46493021083356680
Fox47413021083326999
PS,48523021083356780
et494430210833456
al.50123021083324759
Thickness50843021083327185117146185219246272
of536830210833756
superficial5437302108325621011361563937312108317336579110125
basal40743121083387096128143
cell4229312108331647993
carcinoma43343121083316383114128165202259291
(SBCC)46373121083184983123160180
predicts48293121083385992131145176200227
imiquimod50683121083147085123159174230268306
efficacy:5386312108334526987118150181214227
a3937322108332
proposal39893221083386097137176202235251
for42603221083185677
a4357322108332
thickness-based44093221083216075107137176211238264285325358385420459
definition48883221083387391108146161183199237275
of518332210833756
SBCC.525932210833368109147160
British5439322108335577295110136174
Journal393733210832462101122160193208
of416033210833857
Dermatology.423233210834681102161193215252268306345377387
2013;169(3):549-554.463533210833468100130141171202236255289306318353388422445479512547559
31.39373420085366981
Łasińska40323421083326592106144170200234
I,428034210831528
Zielińska43223421083385388103118156182212245
A,458234210834155
Mackiewicz465134210835587119150166201252267299330
J,499534210832437
et504634210833456
al.51163421083324861
Basal51913421083356895128143
cell5349342108331658095
carcinoma:54593421083316485116131393735210833774131162174
Pathology,41233521083346586123161176213251283292
current44273521083306788109142179199
clinical4638352108331466097111142174189
treatment,48393521083214275106127183218255275288
and513935210833168106
potential52573521083387697130167187202233248
use55173521083366296
of393736210833757
lipid4009362108315306984123
nanoparticles.414736210833870108147186219240265280312328362389403
Cancers.456536210834073111143177198225239
2022;14(11):2778.481936210833468101136148178210229261288303315350383417451464
32.39373720085367186
Dourmishev403637210834584122143201216242280315347
LA,43963721083317488
Rusinova44973721083357399114151189221254
D,476437210834556
Botev48333721083357395129161
I.500737210831528
Clinical50483721083395469107122154187202
variants,52633721083316485101133171192220232
stages,55083721083264982393738210833873100113
and407038210833169108
management419838210835890128160199234292327365387
of460538210833756
basal46813821083397298131147
cell4848382108331648095
carcinoma.49633821083316485116131169208266298311
Indian52943821083155392107139177
Dermatology549138210834581102393739210835790111148164202242274
Online422639210834786101116154189
Journal.443139210832462100121160192208221
2013;4(1):12.466739210833468100130141176195227242253283313326
KNIŽNÍ32656380286124271329430579637
NOVINKA101956380286148316448503653777930
Nina141862540106395488117
Benáková154962540106346599129157189218248
a18116254010629
kol.18546254010629607691
MODERNÍ14186409010972134194238285345366
FARMAKOTERAPIE1801640901094494142214269317376419464511567614634678
V24966409010950
DERMATOLOGII25636409010960105152224279317378420479538559580
2.1418653901094665
doplněné15006539010951100151172221266315360
vydání1877653901094489138181230250
Druhé1418673201075885134182226
doplněné1662673201074997147167214258306351
vydání2030673201074184133173221240
mimořádně2287673201077493166215241283332380424
úspěšné2729673201074881130175208256300
publikace,3047673201074998147167185223265306348363
která3427673201073869112138180
zásadně3624673201073779112154204252296
ovlivnila3937673201074888108126167217235254294
preskripci4249673201075077119153191219238288329347
léků4614673201071963101149
v47816732010740
české4839673201074082116154197
a50536732010741
slovenské5112673201073352100141184232265303346
dermatologii.547567320107499312014186867010774114142188208256306325343359
Autorský17996867010753100128174201236273316
kolektiv2137686701073885105149187218237278
složený2437686701073352100136179227265
z27246867010736
uznávaných2782686701074885134174214256304342382430
odborníků3234686701074898147196223272291331379
se3634686701073478
zaměřuje3734686701073679152196222270289333
na4089686701074889
praktické4200686701074976118156187205246284327
konkrétní4548686701073986134172200243271320338
návody4908686701074889129176226266
k51966867010738
preskripci.5256686701075077120154191219238288329348364
Publikace1418700201074592142161180217260300343
je1777700201071963
určena1856700201074874113155203244
jak211670020107195997
pro2229700201075077124
každodenní2369700201073880117166214264308356404423
použití2808700201074998147183203231249
v30737002010741
praxi,3130700201075077118158177192
tak3338700201072869107
pro3461700201075077124
přípravu360170020107507696145172214253302
ke3919700201073881
specializačním4016700201073483128169188228247265302344384432451524
zkouškám.4556700201073775122171203241284357373
Aktuální4945700201075391122170210229277296
informace525770020107186690137164239279320362
na1418713701074889
úrovni1527713701074774121161210229
roku1775713701072774113161
2023,1956713701074386128172186
včetně2162713701074180123150199243
biologické2424713701075069117137185235254294332375
a28197137010741
molekulárně28797137010774123142186224273292332358407451
cílené335071370107405980124172216
léčby.3586713701071963104153192204
Maxdorf14187324010770109147194240265290
2023,1724732401074486125167180
7281920732401074486126
str.,20627324010734618697110
edice2189732401074391108147187
Jessenius,2393732401073173105136179225242287319333
ISBN:2742732401071958100156169
978-80-7345-766-2,2945732401074484124151195237266303344387427453490528572599636650
Cena:3611732401075192138177190
1195Kč,3817732401074496132173226263277
Formát:4110732401074287113185224249264
160×225mm,4390732401074481124186237279322403475489
brožovaná4895732401074974120154199237277323362
Maxdorf,14187511010770111151199247274301314
s.1752751101073350
r.1813751101072739
o.,186375110107486479
Na1962751101075798
Šejdru2080751101074286105154180229
247/6a,2328751101074484125149190232248
1422596751101074483124
002739751101074490
Praha2849751101074571112160201
4,3070751101074458
tel.:314875110107287090106121
2413289751101074484122
0113431751101074484118
681–9,3569751101074489129170214226
fax:3815751101072366105122
2413957751101074484122
7104099751101074484124
245,4243751101074484125139
www.maxdorf.cz,44017511010765133201214289329369417466493519533574612629
e-mail:1418764101074473147188207225240
info@maxdorf.cz167876410107196790138204278318358406455482508522563601